SCHEMBL4927619

SCHEMBL4927619

Nc1nccc(-c2ccc(C(=O)N3CCc4ccccc4C3)s2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ ALDH1A1 P00352 10/20 0.53
▸ MAPT P10636 6/20 0.53
▸ HTT P42858 5/20 0.53
▸ GAA P10253 3/20 0.46
▸ HPGD P15428 10/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ KDM4E B2RXH2 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ GLA P06280 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44
▸ MAOB P27338 1/20 0.43
▸ LMNA P02545 4/20 0.43
▸ TSHR P16473 3/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ USP2 O75604 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929238 0.83 HDAC1 (0.58) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL4927383 0.79 SMN1; SMN2 (0.63) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL4926706 0.78 NPC1 (0.62) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL19396253 0.74 NPC1 (0.56) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL5000362 0.71 CDC7 (0.54) ALDH1A1KDM4E
SCHEMBL4923314 0.71 KDM4E (0.55) NPC1RAB9AALDH1A1GAAMEN1
SCHEMBL2057844 0.71 ALDH1A1 (0.56) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL4929201 0.69 TAS1R3 (0.51) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL4929466 0.69 NPC1 (0.58) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL4919682 0.68 TAS1R3 (0.60) ALDH1A1HTTKMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 — — US disclosed
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 — — US disclosed
US-20080293716-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-11-27 — — US disclosed
EP-1708697-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-11-28 — — EP disclosed
EP-1708697-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-11 — — EP disclosed
WO-2005074642-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293716-A1 Chemical Compounds CYP11B2, CYP11B1, REN NPC1 204/4885RAB9A 1684/4885ALDH1A1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback